Previous Study: BCIRG 103
Next Study: TORI L-03

Studies & Results


A Randomized Phase 2 Trial of Double-Blind, Placebo Controlled AMG 706 in Combination with Paclitaxel, or Open-Label Bevacizumab in Combination with Paclitaxel, as First Line Therapy in Women with HER2 Negative Locally Recurrent or Metastatic Breast Cancer

View FDA Study


San Antonio Breast Cancer Symposium, 2009

Mackey J, Hurvitz S, Crown J, et al

CIRG/TORI 010: 10-Month Analysis of a Randomized Phase II Trial of Motesanib Plus Weekly Paclitaxel as First Line Therapy in HER2-Negative Metastatic Breast Cancer.

ESMO/ECCO Congress, 2009

Martin M, Hurvitz S, Kennedy J, et al

10-months analysis of a randomized, placebo controlled, phase II trial of motesanib plus weekly paclitaxel as first line therapy in HER2 - negative metastatic breast cancer.


Martin M, Roche H, Pinter T, et al: Motesanib, or open-label bevacizumab, in combination with paclitaxel, as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a phase 2, randomised, double-blind, placebo-controlled study. Lancet Oncol 12:369–376, 2011

For information on any of TRIO's clinical trials, please contact Valérie Bee, Director Project Management at